预防猴痘的JYNNEOS疫苗接种后心脏事件
本研究为回顾性队列研究,纳入2126名至少接种1剂JYNNEOS疫苗者,通过电子健康记录筛查心脏不良事件特别关注(AESI)。经医生裁定确认10例心脏AESI,发生率为每1000剂3.1例(精确95%CI 1.5至5.7),但均不能直接归因于疫苗接种;无住院或严重不良结局归因于接种。
要点
- 2126名至少接种1剂JYNNEOS疫苗者中,经裁定确认10例心脏AESI,发生率每1000剂3.1例(95%CI 1.5至5.7)。
- 所有10例心脏事件均有其他解释,不能直接归因于疫苗接种。
- 无住院或严重不良结局归因于JYNNEOS疫苗接种。
核心结论
- 本回顾性队列研究识别出10例心脏事件,均有其他解释,无住院或严重不良结局归因于JYNNEOS疫苗接种。
研究设计与样本
- 回顾性队列研究,纳入2126名至少接种1剂JYNNEOS疫苗的患者,检索Kaiser Permanente Northwest数据库(包括电子健康记录)以评估心脏不良事件特别关注(AESI)。
主要发现
- 经医生裁定,确认10例心脏AESI,发生率为每1000剂3.1例(精确95%CI 1.5至5.7)。
- 无一例心脏事件可直接归因于疫苗接种。
- 无住院或严重不良结局归因于疫苗接种。
关键数值与推荐
- 免疫实践咨询委员会(ACIP)指出,有基础心脏危险因素者应被告知接种后发生心肌心包炎的理論风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence of cardiac adverse events following JYNNEOS vaccination for prevention of mpox is unknown, however the Advisory Committee on Immunization Practices states that people with underlying cardiac risk factors should be counseled about the theoretical risk for myopericarditis following vaccination. We conducted a retrospective cohort study of 2,126 patients who were vaccinated with at least 1 dose of JYNNEOS vaccine and searched the Kaiser Permanente Northwest databases, including the electronic health record, to evaluate for cardiac adverse events of special interest (AESI). After physician adjudication, there were 10 confirmed cardiac AESI for an incidence of 3.1 per 1000 doses (exact 95% CI, 1.5 to 5.7), however none of these events could be directly attributed to vaccination. This retrospective cohort study of JYNNEOS vaccination for prevention of mpox identified 10 cardiac events that all had alternative explanations; and no hospitalizations or serious adverse outcomes were attributed to vaccination.
引用
- Sharff KA, Tandy TK, Lewis PF, et al. Cardiac events following JYNNEOS vaccination for prevention of Mpox. Vaccine. 2023. PMID: 37117055. doi:10.1016/j.vaccine.2023.04.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。